Christine Lehmann, MA | Authors


Immunotherapy and TKI Combinations Are Emerging as Standard of Care in Advanced RCC

April 18, 2019

The results of several studies presented at the 2019 Genitourinary Cancers Symposium confirmed that the combination of PD-1/PD-L1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway was superior to VEGF inhibitors alone in patients with clear cell renal cell carcinoma, which accounts for about 70% of patients with kidney cancer.

Liver Cancer Treatment Paradigm Undergoing Major Overhaul

October 15, 2018

Until recently, few systemic therapies had been approved for the treatment of patients with liver cancer, as few agents could demonstrate significant benefit over placebo. Sorafenib was the first systemic therapy that extended median overall survival over placebo by nearly 3 months,1 and, in December 2007, it became the first systemic therapy approved by the FDA for patients with unresectable hepatocellular carcinoma.